In our profiling assay, we found that spironolactone also inhibits HTR2A, and antagonists to HTR2A are frequently used for the treatment of schizophrenia,82 suggesting that such a polypharmacological profile may be beneficial for alleviating symptoms in schizophrenic patients. The gene discussed is HTR2A; the disease is schizophrenia.